Search research articles
Contact Us
Filters
Showing results (41-50 of 239) with videos related to
Page
of 24
Sort By:
ACS Medicinal Chemistry Letters
|
May 20, 2026
Targeted Modulation of YAP Signaling: Advancing Small-Molecule Strategies in Oncology and Tissue Regeneration
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
June 17, 2026
Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer Therapy
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
June 17, 2026
Targeted Protein Degradation and Metabolic Inhibition as Complementary Therapeutic Strategies: TEAD PROTACs and NAT8L Inhibitors in Oncology
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
June 17, 2026
Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer
Anna C Renner, Robert B Kargbo
Parasitology Research
|
January 1, 1988
Treatment of fish parasites. 3. Effects of levamisole HCl, metrifonate, fenbendazole, mebendazole, and ivermectin on Anguillicola crassus (nematodes) pathogenic in the air bladder of eels
H Taraschewski, C Renner, H Mehlhorn
ACS Medicinal Chemistry Letters
|
January 14, 2026
Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT Formulations
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
November 19, 2025
LRRK2 Degraders for Parkinson's Disease and Inflammation: Tau and α‑Synuclein Degraders for Neurodegeneration
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
February 18, 2026
Multimodal Modulation of the IL-17 Axis: Integrating Small-Molecule Inhibition, PEGylation, and Targeted Nanoparticle Immunotherapy
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
February 18, 2026
Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics
Anna C Renner, Robert B Kargbo
Leukemia
|
April 1, 1997
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects
C Renner, L Trümper, M Pfreundschuh
Page
of 24
Search research articles
Search
Showing results (41-50 of 239) with videos related to
Sort By:
Page
of 24
ACS Medicinal Chemistry Letters
|
May 20, 2026
Targeted Modulation of YAP Signaling: Advancing Small-Molecule Strategies in Oncology and Tissue Regeneration
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
June 17, 2026
Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer Therapy
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
June 17, 2026
Targeted Protein Degradation and Metabolic Inhibition as Complementary Therapeutic Strategies: TEAD PROTACs and NAT8L Inhibitors in Oncology
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
June 17, 2026
Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer
Anna C Renner, Robert B Kargbo
Parasitology Research
|
January 1, 1988
Treatment of fish parasites. 3. Effects of levamisole HCl, metrifonate, fenbendazole, mebendazole, and ivermectin on Anguillicola crassus (nematodes) pathogenic in the air bladder of eels
H Taraschewski, C Renner, H Mehlhorn
ACS Medicinal Chemistry Letters
|
January 14, 2026
Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT Formulations
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
November 19, 2025
LRRK2 Degraders for Parkinson's Disease and Inflammation: Tau and α‑Synuclein Degraders for Neurodegeneration
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
February 18, 2026
Multimodal Modulation of the IL-17 Axis: Integrating Small-Molecule Inhibition, PEGylation, and Targeted Nanoparticle Immunotherapy
Anna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters
|
February 18, 2026
Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics
Anna C Renner, Robert B Kargbo
Leukemia
|
April 1, 1997
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects
C Renner, L Trümper, M Pfreundschuh
Page
of 24